GlaxoSmithKline plc (LON:GSK) had its price target reduced by investment analysts at Berenberg Bank from GBX 1,835 ($24.21) to GBX 1,760 ($23.23) in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price objective would indicate a potential upside of 29.65% from the stock’s previous close.
GSK has been the topic of a number of other reports. J P Morgan Chase & Co reissued a “neutral” rating and set a GBX 1,570 ($20.72) price target on shares of GlaxoSmithKline plc in a research note on Monday, October 2nd. Liberum Capital reissued a “buy” rating and set a GBX 1,760 ($23.23) price target on shares of GlaxoSmithKline plc in a research note on Wednesday, October 25th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.07) price target on GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Wednesday, July 26th. BNP Paribas set a GBX 1,620 ($21.38) price target on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, September 6th. Finally, Beaufort Securities reissued a “buy” rating and set a GBX 1,800 ($23.75) price target on shares of GlaxoSmithKline plc in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of GBX 1,619.75 ($21.37).
GlaxoSmithKline plc (LON:GSK) last announced its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%. The firm had revenue of GBX 784.30 billion for the quarter.
In other news, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction dated Thursday, October 12th. The stock was purchased at an average price of GBX 1,527 ($20.15) per share, for a total transaction of £16,430.52 ($21,681.87). Also, insider Urs Rohner acquired 473 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The shares were purchased at an average price of GBX 1,518 ($20.03) per share, with a total value of £7,180.14 ($9,474.98). In the last 90 days, insiders have bought 1,574 shares of company stock valued at $2,398,888.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.